Tirzepatide
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Eli Lilly · Phase 2 · Completed · Enrollment 354
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Dosing scheme a: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme a: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme b: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme b: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme c: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme c: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme d: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme d: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme e: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme e: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme f: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme f: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme g: Tirzepatide | n/r | n/r | n/r | n/r |
Not shown
- Dosing scheme a: NNC0519-0130: endpoint not reported
- Dosing scheme a: Placebo: endpoint not reported
- Dosing scheme b: NNC0519-0130: endpoint not reported
- Dosing scheme b: Placebo: endpoint not reported
- Dosing scheme c: NNC0519-0130: endpoint not reported
- Dosing scheme c: Placebo: endpoint not reported
- Dosing scheme d: NNC0519-0130: endpoint not reported
- Dosing scheme d: Placebo: endpoint not reported
- Dosing scheme e: NNC0519-0130: endpoint not reported
- Dosing scheme e: Placebo: endpoint not reported
- Dosing scheme f: NNC0519-0130: endpoint not reported
- Dosing scheme f: Placebo: endpoint not reported
- Dosing scheme g: Tirzepatide: endpoint not reported